“…As an adjuvant, PCP is known for its potential to improve immunogenicity by triggering antigen-specific immune responses against cancer metastasis ( Wu et al, 2016 ; Gai et al, 2017 ; Liu et al, 2020 ). However, owing to its relatively poor stability and untargeted features ( Zhao et al, 2022 ), PCP is limited in clinical applications. Recently, the construction of nanoparticles has been shown to reduce drug loss during delivery, enhance the solubility of hydrophobic drugs, improve drug targeting, and extend drug release ( Dudek et al, 2016 ; Wen et al, 2019 ).…”